| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 100/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Appearance | white powder |
| CAS | 1256580-46-7 |
| Assay | 99% |
| Keywords | Alectinib;Alectinib Powder;Alectinib HCl |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
Alectinib is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been cl inically evaluated for the treatment of patients with ALK-driven tumors.
Treatment of Non-Small Cell Lung Cancer (NSCLC): Alectinib is primarily used for the treatment of patients with advanced or metastatic NSCLC that harbors the anaplastic lymphoma kinase (ALK) gene rearrangement.
First-Line Therapy: It is approved as a first-line therapy option for ALK-positive NSCLC patients, offering significant progression-free survival benefits compared to chemotherapy.
Post-Crizotinib Therapy: Alectinib is also indicated for patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.
ALK Inhibition: Alectinib functions by selectively inhibiting the ALK tyrosine kinase activity, which is abnormally activated in ALK-positive NSCLC cells. This inhibition disrupts oncogenic signaling pathways essential for tumor growth and survival.
Tumor Growth Suppression: By blocking ALK signaling, alectinib effectively suppresses the proliferation of cancer cells, leading to tumor growth inhibition and potentially tumor regression.
Central Nervous System (CNS) Penetration: Alectinib demonstrates good CNS penetration, making it effective in treating or preventing brain metastases in ALK-positive NSCLC patients. This feature sets it apart from some other ALK inhibitors.
Improving Survival Outcomes: Clinical trials have shown that alectinib improves progression-free survival and overall survival outcomes for eligible patients, enhancing their quality of life and duration of response.
){kind=link}